Phio Pharmaceuticals 3Q 2026: EPS ($0.36) — 10-Q Summary
Phio Pharmaceuticals reported a wider net loss of $4.16M in 3Q 2026, up 73.9% YoY, due to increased R&D and regulatory costs. EPS was ($0.36). The company advanced PH-762 toward a Phase 2b study, with a 65% response rate in Phase 1b trials. Manufacturing of PH-762 drug substance began in 3Q 2026.
How this was made
The 30-second read
Why it matters
The earnings miss may trigger short‑term selling pressure, but the trial's 65% response rate could attract speculative buying.
Market read
Primary earnings disclosure for a micro‑cap biotech with material trial data; relevant for short‑term traders and biotech-focused investors.
What to watch
Potential upcoming Phase 2b study and cGMP batch production could improve long‑term outlook.
Background
Phio Pharmaceuticals filed its Q3 2026 10‑Q, reporting a deeper net loss and disclosing Phase 1b trial results for its lead candidate PH‑762.
Ticker impact
Q3 2026 net loss widened to $4.16M, EPS -$0.36 and Phase 1b results showing 65% response for PH-762.
likely pressure as the market prices in the larger loss and expense increase
Earnings miss combined with higher costs is a bearish catalyst; however, the 65% response rate in the trial could mitigate the downside.
Market effects
Biotech sector may see modest uplift from positive trial data, but earnings miss could dampen broader sentiment.
Limited to U.S. biotech investors.
Minimal global impact beyond niche biotech community.
Counterpoint
Investors could view the trial data as a catalyst for a future upside despite the earnings miss.
Key entities
- companyPhio Pharmaceuticals
Biotech firm developing PH‑762 for cutaneous squamous cell carcinoma.
